Breaking News Instant updates and real-time market news.

2020-02-04 16:34:24 PDM Piedmont Office Realty $24.02 / +0.47 (+2.00%) 16:34 02/04/20 02/04 16:34 02/04/20 16:34	Piedmont Office Realty reports Q4 core FFO 46c, consensus 45c Reports Q4 revenue $134.15M, consensus $134.75M. Commenting on the quarter's results, Brent Smith, President and CEO, said, "2019 was a phenomenal year for Piedmont. We completed several key acquisitions which allowed us to gain control of the entire 2.1 million square foot Atlanta Galleria office development. Those acquisitions were funded by the sale of two of our more mature assets in non-strategic markets, including the sale during the fourth quarter of 500 West Monroe Street in Chicago, and demonstrate our ability to monetize assets which have maximized their growth potential in our portfolio and redeploy the proceeds accretively into our targeted sub-markets. Leasing activity for the year was an impressive 2.3 million square feet and resulted in strong current, and what we believe, will be future rent growth. During the fourth quarter we successfully completed an approximately 20-year renewal of one of our largest tenants, State of New York, for more space and at better economics than we originally anticipated. Further, we are very excited about the start we are seeing for 2020 with a significant acquisition planned in Dallas and continued leasing momentum across the portfolio."	05 Feb
PDM Piedmont Office Realty $24.02 / +0.47 (+2.00%) 01/06/20 Baird Piedmont Office Realty upgraded to Outperform from Neutral at Baird 02/07/19 Stifel Piedmont Office Realty upgraded to Hold on better value creation at Stifel 02/06/19 Stifel Piedmont Office Realty upgraded to Hold from Sell at Stifel

2020-02-04 16:34:24

PDM

Piedmont Office Realty

$24.02 / +0.47 (+2.00%)

16:34

02/04/20

02/04

16:34

02/04/20

16:34

Piedmont Office Realty reports Q4 core FFO 46c, consensus 45c

Reports Q4 revenue $134.15M, consensus $134.75M. Commenting on the quarter's results, Brent Smith, President and CEO, said, "2019 was a phenomenal year for Piedmont. We completed several key acquisitions which allowed us to gain control of the entire 2.1 million square foot Atlanta Galleria office development. Those acquisitions were funded by the sale of two of our more mature assets in non-strategic markets, including the sale during the fourth quarter of 500 West Monroe Street in Chicago, and demonstrate our ability to monetize assets which have maximized their growth potential in our portfolio and redeploy the proceeds accretively into our targeted sub-markets. Leasing activity for the year was an impressive 2.3 million square feet and resulted in strong current, and what we believe, will be future rent growth. During the fourth quarter we successfully completed an approximately 20-year renewal of one of our largest tenants, State of New York, for more space and at better economics than we originally anticipated. Further, we are very excited about the start we are seeing for 2020 with a significant acquisition planned in Dallas and continued leasing momentum across the portfolio."

05
Feb

PDM Piedmont Office Realty

$24.02 / +0.47 (+2.00%)

01/06/20 Baird: Piedmont Office Realty upgraded to Outperform from Neutral at Baird

02/07/19 Stifel: Piedmont Office Realty upgraded to Hold on better value creation at Stifel

02/06/19 Stifel: Piedmont Office Realty upgraded to Hold from Sell at Stifel

TODAY'S FREE FLY STORIES

Hot Stocks	Weis Markets CFO Scott Frost to retire, Michael Lockard to succeed » 05:28 01/20/21 01/20 05:28 01/20/21 05:28 WMK Weis Markets $47.52 / -0.97 (-2.00%) Weis Markets announced… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial
Downgrade	Novo Nordisk downgraded to Neutral from Outperform at Credit Suisse » 05:28 01/20/21 01/20 05:28 01/20/21 05:28 NVO Novo Nordisk $73.01 / +0.99 (+1.37%) Credit Suisse analyst… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings On The Fly Options NVO Novo Nordisk $73.01 / +0.99 (+1.37%) 01/05/21 Dicerna announces first Novo Nordisk nominated candidate under agreement 01/04/21 Novo Nordisk extends COVID-19 Patient Assistance Program until June 30, 2021 12/29/20 Novo Nordisk files for EU approval of once-weekly semaglutide to treat T2D 12/18/20 Novo Nordisk files for EU approval of once-weekly semaglutide to manage weight NVO Novo Nordisk $73.01 / +0.99 (+1.37%) 01/15/21 Deutsche Bank Novo Nordisk initiated with a Buy at Deutsche Bank 11/16/20 Piper Sandler Piper says 'underwhelming' data from Novo Nordisk a 'big win' for Intercept 11/12/20 JPMorgan Novo Nordisk price target lowered to DKK 470 from DKK 480 at JPMorgan 11/06/20 Morgan Stanley Novo Nordisk downgraded to Underweight from Equal Weight at Morgan Stanley NVO Novo Nordisk $73.01 / +0.99 (+1.37%) 10/30/20 Novo Nordisk reports operating profit up 7% at CER in first nine months of 2020 10/08/20 Novo Nordisk boosts 2020 sales growth outlook to 5%-8% from 3%-6% 10/08/20 Novo Nordisk raises sales, operating profit outlook for 2020 08/06/20 Novo Nordisk backs view of 2020 sales growth of 3-6% at CER NVO Novo Nordisk $73.01 / +0.99 (+1.37%) 09/30/20 Before the Move: Watch Novo Nordisk, Bristol into AASLD abstract publication NVO Novo Nordisk $73.01 / +0.99 (+1.37%) 12/16/20 Unusually active option classes on open December 16th
Downgrade	Schweiter downgraded to Add from Buy at Baader Helvea » 05:27 01/20/21 01/20 05:27 01/20/21 05:27 SCWTF Schweiter $0.00 / + (+0.00%) Baader Helvea analyst… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Street Research SCWTF Schweiter $0.00 / + (+0.00%) 05/26/20 UBS Schweiter price target lowered to CHF 1,080 from CHF 1,200 at UBS
Upgrade	Boeing upgraded to Hold from Sell at Berenberg » 05:27 01/20/21 01/20 05:27 01/20/21 05:27 BA Boeing $210.66 / +6.41 (+3.14%) Berenberg analyst Andrew… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Periodicals On The Fly Events Options BA Boeing $210.66 / +6.41 (+3.14%) 01/19/21 Boeing reports BBAM to add up to 12 737-800 converted freighters 01/18/21 Air Canada to resume Boeing 737 MAX commercial operations on Feb. 1 01/12/21 Boeing awarded $1.69B Air Force contract modification for KC-46 aircraft 01/12/21 Boeing reports 59 commercial airplane deliveries in Q4 BA Boeing $210.66 / +6.41 (+3.14%) 01/04/21 Fly Intel: Top five analyst downgrades 01/04/21 Baird Boeing elevated to Fresh Pick at Baird 01/04/21 Bernstein Bernstein downgrades Boeing to Underperform on worsening 787 outlook 01/04/21 Bernstein Boeing downgraded to Underperform from Market Perform at Bernstein BA Boeing $210.66 / +6.41 (+3.14%) 10/28/20 Boeing reports Q3 core EPS ($1.39), consensus ($2.32) 10/27/20 Notable companies reporting before tomorrow's open 10/27/20 Notable companies reporting before tomorrow's open 07/29/20 Boeing reports Q2 core EPS ($4.79), consensus ($2.54) BA Boeing $210.66 / +6.41 (+3.14%) 01/13/21 Emirates President: Boeing 777X entry likely in 2023 or later, Reuters says 01/13/21 Boeing's drone unit to pay $25M to settle civil fraud allegations, WSJ reports 01/02/21 Congress overturns Trump veto on Defense bill, NPR reports 12/31/20 U.S. amends duties on EU goods in Airbus, Boeing dispute, Bloomberg says BA Boeing $210.66 / +6.41 (+3.14%) 01/11/21 Fly Intel: Wall Street's top stories for Monday 01/11/21 Fly Intel: Wall Street's top stories at midday 01/08/21 Fly Intel: Wall Street's top stories for Friday 01/08/21 Fly Intel: Wall Street's top stories at midday 01/27/21 Boeing - BA BA Boeing $210.66 / +6.41 (+3.14%) 12/07/20 Early notable gainers among liquid option names on December 7th 12/03/20 Unusually active option classes on open December 3rd 12/02/20 Boeing call volume above normal and directionally bullish 11/19/20 Notable open interest changes for November 19th
Downgrade	Gerdau downgraded to Hold from Buy at HSBC » 05:24 01/20/21 01/20 05:24 01/20/21 05:24 GGB Gerdau $4.76 / -0.12 (-2.46%) HSBC analyst Jonathan… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Street Research GGB Gerdau $4.76 / -0.12 (-2.46%) 01/12/21 Goldman Sachs Gerdau downgraded to Neutral from Buy at Goldman Sachs 12/15/20 Morgan Stanley Gerdau upgraded to Overweight from Equal Weight at Morgan Stanley 10/07/20 Bradesco BBI Gerdau upgraded to Outperform from Neutral at Bradesco BBI 10/07/20 Bradesco BBI Gerdau upgraded to Outperform from Neutral at Bradesco BBI

Downgrade	Grupo Financiero Banorte downgraded to Hold from Buy at HSBC » 05:22 01/20/21 01/20 05:22 01/20/21 05:22 GBOOF Grupo Financiero Banorte $0.00 / + (+0.00%) HSBC analyst Carlos… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Street Research GBOOF Grupo Financiero Banorte $0.00 / + (+0.00%) 10/27/20 Citi Grupo Financiero Banorte downgraded to Neutral from Buy at Citi 10/13/20 Credit Suisse Banorte upgraded to Outperform from Underperform at Credit Suisse 06/17/20 Goldman Sachs Grupo Financiero Banorte initiated with a Buy at Goldman Sachs 05/14/20 Credit Suisse Banorte downgraded to Underperform from Neutral at Credit Suisse
Hot Stocks	Alcon launches PRECISION1 contact lens in the U.S. » 05:22 01/20/21 01/20 05:22 01/20/21 05:22 ALC Alcon $72.68 / +2.57 (+3.67%) Alcon announced the U.S.… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings On The Fly Options ALC Alcon $72.68 / +2.57 (+3.67%) 11/10/20 Alcon not providing FY20 guidance 08/18/20 Alcon cannot estimate FY20 due to COVID-19 ALC Alcon $72.68 / +2.57 (+3.67%) 01/07/21 KeyBanc Veeva initiated with an Overweight at KeyBanc 11/19/20 Berenberg Alcon price target raised to CHF 69 from CHF 62 at Berenberg 11/16/20 JPMorgan Alcon price target raised to CHF 57 from CHF 55 at JPMorgan 11/12/20 Jefferies Alcon price target raised to $78 from $71 at Jefferies ALC Alcon $72.68 / +2.57 (+3.67%) 11/10/20 Alcon reports Q3 EPS 39c, consensus 22c 08/18/20 Alcon reports Q2 EPS (21c), consensus (15c) ALC Alcon $72.68 / +2.57 (+3.67%) 11/10/20 Fly Intel: After-Hours Movers ALC Alcon $72.68 / +2.57 (+3.67%) 08/18/20 Alcon options imply 7.8% move in share price post-earnings
Upgrade	CK Infrastructure upgraded to Buy from Hold at HSBC » 05:22 01/20/21 01/20 05:22 01/20/21 05:22 CKISY CK Infrastructure $0.00 / + (+0.00%) HSBC analyst Evan Li… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial
Upgrade	Banco Santander upgraded to Buy from Hold at HSBC » 05:21 01/20/21 01/20 05:21 01/20/21 05:21 SAN Banco Santander $3.29 / +0.005 (+0.15%) HSBC analyst Domenico… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Periodicals On The Fly Options SAN Banco Santander $3.29 / +0.005 (+0.15%) 12/15/20 ECB asks banks to refrain from or limit dividends until September 2021 12/15/20 ECB asks banks to refrain from or limit dividends until September 2021 11/16/20 Santander agrees to acquire technology assets from Wirecard 07/31/20 SHUSA's request approved for certain exceptions to FRB interim policy SAN Banco Santander $3.29 / +0.005 (+0.15%) 01/19/21 Barclays Banco Santander price target raised to EUR 3.10 from EUR 2.90 at Barclays 01/15/21 Morgan Stanley Banco Santander price target raised to EUR 3.50 from EUR 3.30 at Morgan Stanley 01/11/21 Deutsche Bank Banco Santander price target raised to EUR 2.85 from EUR 2.80 at Deutsche Bank 01/11/21 UBS Banco Santander upgraded to Buy from Neutral at UBS SAN Banco Santander $3.29 / +0.005 (+0.15%) 10/30/20 Santander Chile reports Q3 EPS 28c, consensus 26c SAN Banco Santander $3.29 / +0.005 (+0.15%) 11/13/20 Santander plans to cut 4,000 positions, Reuters reports SAN Banco Santander $3.29 / +0.005 (+0.15%) 11/16/20 Fly Intel: Wall Street's top stories for Monday 09/11/20 The Intersection: Crypto and Wall Street This Week SAN Banco Santander $3.29 / +0.005 (+0.15%) 12/21/20 Unusually active option classes on open December 21st 09/22/20 Largest borrow rate increases among liquid names 09/21/20 Largest borrow rate increases among liquid names 09/18/20 Largest borrow rate increases among liquid names
Downgrade	Arjo downgraded to Sell from Hold at Nordea » 05:20 01/20/21 01/20 05:20 01/20/21 05:20 ARRJF Arjo $0.00 / + (+0.00%) Nordea analyst Sten… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial

Hot Stocks	Amryt receives NICE approval for Myalepta reimbursement in England, Wales » 05:19 01/20/21 01/20 05:19 01/20/21 05:19 AMYT Amryt Pharma $13.49 / + (+0.00%) Amryt announced that the… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research AMYT Amryt Pharma $13.49 / + (+0.00%) 12/23/20 Amryt Pharma granted orphan drug designation from FDA for AP103 12/17/20 Amryt Pharma receives Saudi Arabia reimbursement approval for Lojuxta 12/09/20 Amryt Pharma receives marketing authorization for Lojuxta in Brazil 10/29/20 Amryt Pharma announces Phase 3 EASE trial of Filsuvez meets primary endpoint AMYT Amryt Pharma $13.49 / + (+0.00%) 07/20/20 Fly Intel: Top five analyst initiations 07/20/20 Canaccord Amryt Pharma initiated with a Buy at Canaccord 07/09/20 Fly Intel: Top five analyst initiations 07/08/20 Cantor Fitzgerald Cantor Fitzgerald starts Amryt at Overweight, sees number of catalysts upcoming
Upgrade	Daimler AG upgraded to Buy from Hold at HSBC » 05:19 01/20/21 01/20 05:19 01/20/21 05:19 DDAIF Daimler AG $0.00 / + (+0.00%) HSBC analyst Henning… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Periodicals On The Fly DDAIF Daimler AG $0.00 / + (+0.00%) 01/19/21 EU passenger car registrations down 3.3% in December 12/31/20 Daimler Trucks fined $30M by NHTSA over slow vehicle recalls 12/22/20 Daimler AG, Infosys announce long-term IT infrastructure partnership 12/17/20 EU passenger car registrations down 12.0% in November DDAIF Daimler AG $0.00 / + (+0.00%) 01/14/21 R.F. Lafferty Luminar initiated with a Buy at R.F. Lafferty 01/08/21 Deutsche Bank Daimler AG named short-term investment idea at Deutsche Bank 01/07/21 Deutsche Bank Daimler AG price target raised to EUR 70 from EUR 60 at Deutsche Bank 11/27/20 Exane BNP Paribas Exane double upgrades Daimler on Mercedes electric car potential DDAIF Daimler AG $0.00 / + (+0.00%) 10/23/20 Daimler AG reports Q3 EPS EUR 1.92 vs. EUR 1.61 last year 10/15/20 Daimler AG sees Q3 adj. EBIT EUR 3.48B 10/15/20 Daimler AG sees Q3 'above market expectations' 07/23/20 Daimler AG reports Q2 EPS (EUR1.87) vs. (EUR1.24) last year DDAIF Daimler AG $0.00 / + (+0.00%) 11/17/20 Daimler, Geely to collaborate over next-gen combustion engines, Reuters says 11/16/20 Quebec to prohibit sale of new gas-powered cars as of 2035, Reuters says 11/11/20 Mercedes-Benz Berlin factory head to join Tesla, Reuters says 10/14/20 Daimler CEO remains committed to F1 but working to cut costs, Reuters says DDAIF Daimler AG $0.00 / + (+0.00%) 08/17/20 Analysts bullish on Nvidia, up targets ahead of quarterly results
Hot Stocks	Calliditas Therapeutics to provide data from Part A of NefIgArd study » 05:17 01/20/21 01/20 05:17 01/20/21 05:17 CALT Calliditas Therapeutics $31.90 / +1.35 (+4.42%) Calliditas Therapeutics… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Syndicate Events CALT Calliditas Therapeutics $31.90 / +1.35 (+4.42%) 01/18/21 Calliditas says Phase 1 setanaxib trial shows favorable pharmacokinetic profile 11/09/20 Calliditas Therapeutics says Part A of NefIgArd trial met its primary objective CALT Calliditas Therapeutics $31.90 / +1.35 (+4.42%) 07/01/20 Citi Calliditas Therapeutics initiated with a Buy at Citi 06/30/20 Jefferies Calliditas Therapeutics initiated with a Buy at Jefferies 06/30/20 Stifel Calliditas Therapeutics initiated with a Buy at Stifel 05 Jun 07:00 Today Calliditas Therapeutics
Downgrade	Elkem ASA downgraded to Hold from Buy at DNB Markets » 05:17 01/20/21 01/20 05:17 01/20/21 05:17 ELKEF Elkem ASA $0.00 / + (+0.00%) DNB Markets analyst… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Street Research ELKEF Elkem ASA $0.00 / + (+0.00%) 06/24/20 Citi Elkem ASA downgraded to Sell from Neutral at Citi 03/30/20 Morgan Stanley Elkem ASA price target lowered to NOK 17 from NOK 21 at Morgan Stanley
Upgrade	Cairn Energy upgraded to Add from Hold at Peel Hunt » 05:16 01/20/21 01/20 05:16 01/20/21 05:16 CRNCY Cairn Energy $0.00 / + (+0.00%) Peel Hunt analyst Werner… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Street Research CRNCY Cairn Energy $0.00 / + (+0.00%) 01/12/21 Morgan Stanley Cairn Energy price target raised to 250 GBp from 248 GBp at Morgan Stanley 01/11/21 RBC Capital Cairn Energy price target raised to 300 GBp from 150 GBp at RBC Capital 01/11/21 Barclays Cairn Energy price target raised to 315 GBp from 235 GBp at Barclays 12/24/20 AlphaValue Cairn Energy upgraded to Add from Sell at AlphaValue

Upgrade	Trainline upgraded to Buy from Hold at Panmure Gordon » 05:15 01/20/21 01/20 05:15 01/20/21 05:15 TNLIY Trainline $0.00 / + (+0.00%) Panmure Gordon analyst… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Street Research TNLIY Trainline $0.00 / + (+0.00%) 01/19/21 Deutsche Bank Trainline price target lowered to 512 GBp from 527 GBp at Deutsche Bank 12/10/20 JPMorgan Trainline price target raised to 486 GBp from 430 GBp at JPMorgan 12/03/20 Stifel Trainline initiated with a Buy at Stifel 10/19/20 Deutsche Bank Trainline initiated with a Buy at Deutsche Bank
Downgrade	Crown Resorts downgraded to Neutral from Outperform at Credit Suisse » 05:13 01/20/21 01/20 05:13 01/20/21 05:13 CWLDF Crown Resorts $0.00 / + (+0.00%) Credit Suisse analyst… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial
Upgrade	Netflix upgraded to Overweight from Equal Weight at Wells Fargo » 05:11 01/20/21 01/20 05:11 01/20/21 05:11 NFLX Netflix $501.85 / +3.9 (+0.78%) Wells Fargo analyst… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Periodicals On The Fly Options NFLX Netflix $501.85 / +3.9 (+0.78%) 01/19/21 Netflix says 'super proud' of free cash flow 01/19/21 Netflix says not necessarily through the 'pull forward' of 2020 01/19/21 Netflix says past year 'testament' to company's approach 01/19/21 Netflix says 'very close to being sustainably FCF positive' NFLX Netflix $501.85 / +3.9 (+0.78%) 05:01 Today Piper Sandler Netflix price target raised to $652 from $643 at Piper Sandler 04:52 Today Pivotal Research Netflix price target raised to $750 from $660 at Pivotal Research 04:41 Today UBS Netflix upgraded to Buy from Neutral at UBS 01/19/21 JPMorgan JPMorgan says buy 'FANG' stocks amid 'fatigue and frustration' NFLX Netflix $501.85 / +3.9 (+0.78%) 01/19/21 Netflix sees Q1 EPS $2.97, consensus $2.10 01/19/21 Netflix reports Q4 EPS $1.19, consensus $1.39 01/19/21 Notable companies reporting after market close 10/20/20 Netflix sees Q4 EPS $1.35, consensus 94c NFLX Netflix $501.85 / +3.9 (+0.78%) 01/15/21 Data suggests Netflix North American usage dipped in Q4, Business Insider says 01/06/21 Netflix raising prices for some UK subscription plans, BBC reports 12/15/20 Netflix streaming experiences outage for over 1,000 users, Reuters says 12/07/20 Netflix sued by Activision over allegedly poaching former CFO, WSJ reports NFLX Netflix $501.85 / +3.9 (+0.78%) 01/19/21 Fly Intel: After-Hours Movers 01/19/21 Fly Intel: What to watch in Netflix earnings report 01/15/21 Spotify plunges after downgrade, report of Apple podcast ambitions 01/15/21 Accolade upgrade, Spotify downgrade among today's top calls on Wall Street NFLX Netflix $501.85 / +3.9 (+0.78%) 01/19/21 Netflix options imply 9.5% move in share price post-earnings 12/31/20 Early notable gainers among liquid option names on December 31st 10/26/20 Early notable gainers among liquid option names on October 26th 10/21/20 Notable open interest changes for October 21st
Downgrade	Bloom Energy downgraded to Neutral from Outperform at Credit Suisse » 05:06 01/20/21 01/20 05:06 01/20/21 05:06 BE Bloom Energy $39.89 / +3.41 (+9.35%) Credit Suisse analyst… Credit Suisse analyst Michael Weinstein downgraded Bloom Energy to Neutral from Outperform with a price target of $32, up from $27. The stock closed Tuesday up 9% to $39.93. The analyst increased the price target to reflect higher 2024 and 2025 growth rates due to a two year federal solar tax credit extension and potentially favorable zero-carbon policy under President Biden. Weinstein, however, downgrades Bloom due to valuation. ShowHide Related Items >><< Company News Street Research Earnings Syndicate Periodicals On The Fly Events Options BE Bloom Energy $39.89 / +3.41 (+9.35%) 12/09/20 Bloom Energy falls -15.3% 11/18/20 Bloom Energy, SK E&C announce they won RFP to supply SOFC in Korea 09/18/20 Bloom Energy rises 18.1% 09/18/20 Bloom Energy rises 10.7% BE Bloom Energy $39.89 / +3.41 (+9.35%) 01/14/21 JPMorgan Bloom Energy price target raised to $35 from $26 at JPMorgan 01/12/21 Morgan Stanley Morgan Stanley downgrades 2020 top performer Bloom Energy to Equal Weight 01/12/21 Morgan Stanley Bloom Energy downgraded to Equal Weight from Overweight at Morgan Stanley 12/21/20 Morgan Stanley Bloom Energy price target raised to $32 from $21 at Morgan Stanley BE Bloom Energy $39.89 / +3.41 (+9.35%) 10/29/20 Bloom Energy reports Q3 net loss $12.0M 07/28/20 Bloom Energy not providing guidance for Q3 07/28/20 Bloom Energy reports preliminary Q2 revenue $187.9M, consensus $171.22M 15 Oct 02 Oct BE Bloom Energy $39.89 / +3.41 (+9.35%) 12/08/20 Rapidly changing industry foiled Bloom Energy's vision, WSJ says 10/14/20 Bloom Energy holder Canada Pension Plan exiting stake, Bloomberg says 07/25/20 Bubble forming in Hydrogen fuel-cell stocks, Barron's says BE Bloom Energy $39.89 / +3.41 (+9.35%) 10/29/20 Fly Intel: After-Hours Movers 10/12/20 Fly Insider: Element Solutions, Sunrun among week's notable insider trades 08/03/20 Fly Insider: Montrose, Centene among week's notable insider transactions 07/28/20 Fly Intel: After-Hours Movers 02/10/21 Bloom Energy - BE BE Bloom Energy $39.89 / +3.41 (+9.35%) 12/08/20 Bloom Energy call volume above normal and directionally bullish 12/04/20 Bloom Energy call volume above normal and directionally bullish 11/24/20 Bloom Energy call volume above normal and directionally bullish 11/23/20 Bloom Energy call volume above normal and directionally bullish
Upgrade	Megaport upgraded to Buy from Neutral at Goldman Sachs » 05:03 01/20/21 01/20 05:03 01/20/21 05:03 MGPPF Megaport $0.00 / + (+0.00%) Goldman Sachs analyst… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News Street Research MGPPF Megaport $0.00 / + (+0.00%) 08/17/20 Megaport announces upcoming release of Megaport Virtual Edge MGPPF Megaport $0.00 / + (+0.00%) 08/06/20 Canaccord Megaport upgraded to Buy from Hold at Canaccord

Recommendations	Netflix price target raised to $652 from $643 at Piper Sandler » 05:01 01/20/21 01/20 05:01 01/20/21 05:01 NFLX Netflix $501.85 / +3.9 (+0.78%) Piper Sandler analyst… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Periodicals On The Fly Options NFLX Netflix $501.85 / +3.9 (+0.78%) 01/19/21 Netflix says 'super proud' of free cash flow 01/19/21 Netflix says not necessarily through the 'pull forward' of 2020 01/19/21 Netflix says past year 'testament' to company's approach 01/19/21 Netflix says 'very close to being sustainably FCF positive' NFLX Netflix $501.85 / +3.9 (+0.78%) 04:52 Today Pivotal Research Netflix price target raised to $750 from $660 at Pivotal Research 04:41 Today UBS Netflix upgraded to Buy from Neutral at UBS 01/19/21 JPMorgan JPMorgan says buy 'FANG' stocks amid 'fatigue and frustration' 01/15/21 Citi Citi cuts Spotify to Sell with no benefit seen on podcast investments NFLX Netflix $501.85 / +3.9 (+0.78%) 01/19/21 Netflix sees Q1 EPS $2.97, consensus $2.10 01/19/21 Netflix reports Q4 EPS $1.19, consensus $1.39 01/19/21 Notable companies reporting after market close 10/20/20 Netflix sees Q4 EPS $1.35, consensus 94c NFLX Netflix $501.85 / +3.9 (+0.78%) 01/15/21 Data suggests Netflix North American usage dipped in Q4, Business Insider says 01/06/21 Netflix raising prices for some UK subscription plans, BBC reports 12/15/20 Netflix streaming experiences outage for over 1,000 users, Reuters says 12/07/20 Netflix sued by Activision over allegedly poaching former CFO, WSJ reports NFLX Netflix $501.85 / +3.9 (+0.78%) 01/19/21 Fly Intel: After-Hours Movers 01/19/21 Fly Intel: What to watch in Netflix earnings report 01/15/21 Spotify plunges after downgrade, report of Apple podcast ambitions 01/15/21 Accolade upgrade, Spotify downgrade among today's top calls on Wall Street NFLX Netflix $501.85 / +3.9 (+0.78%) 01/19/21 Netflix options imply 9.5% move in share price post-earnings 12/31/20 Early notable gainers among liquid option names on December 31st 10/26/20 Early notable gainers among liquid option names on October 26th 10/21/20 Notable open interest changes for October 21st
Downgrade	ShockWave Medical downgraded to Neutral from Overweight at Piper Sandler » 05:00 01/20/21 01/20 05:00 01/20/21 05:00 SWAV ShockWave Medical $142.06 / +5 (+3.65%) Piper Sandler analyst… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Syndicate Events SWAV ShockWave Medical $142.06 / +5 (+3.65%) 12/04/20 ShockWave Medical says CMS creates four new codes for IVL procedures 11/08/20 ShockWave announces unveiling of data from Disrupt PAD III study 10/15/20 ShockWave reports Disrupt CAD III met primary safety, effectiveness endpoints 10/01/20 ShockWave Medical announces updated time for CAD III Investor Webcast Event SWAV ShockWave Medical $142.06 / +5 (+3.65%) 01/13/21 Piper Sandler MCIT finalized rule 'important win' for medical technology, says Piper Sandler 01/12/21 Wells Fargo ShockWave Medical price target raised to $134 from $95 at Wells Fargo 12/03/20 Piper Sandler Piper boosts ShockWave Medical target to $96, likes setup into 2021 12/02/20 Oppenheimer Oppenheimer stays at Perform on ShockWave, highlights paper on IVL-induced VFib SWAV ShockWave Medical $142.06 / +5 (+3.65%) 11/09/20 ShockWave Medical reports Q3 EPS (38c), consensus (55c) 08/11/20 ShockWave Medical reports Q2 EPS (56c), consensus (62c) 17 Jun 02/17/21 ShockWave Medical - SWAV
Downgrade	Global Blood downgraded to Neutral from Overweight at Piper Sandler » 04:58 01/20/21 01/20 04:58 01/20/21 04:58 GBT Global Blood Therapeutics $50.81 / +0.83 (+1.66%) Piper Sandler analyst… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings On The Fly GBT Global Blood Therapeutics $50.81 / +0.83 (+1.66%) 01/07/21 Global Blood Therapeutics announces employment inducement grants 12/07/20 Global Blood Therapeutics appoints Kim Smith-Whitley as head of R&D 12/06/20 Global Blood presents new data on long-term, real-world use of Oxbryta tablets 12/06/20 Global Blood presents data on new sickle cell disease pipeline therapies GBT Global Blood Therapeutics $50.81 / +0.83 (+1.66%) 12/15/20 H.C. Wainwright Global Blood Therapeutics assumed with a Buy at H.C. Wainwright 12/03/20 Fly Intel: Top five analyst initiations 12/03/20 RBC Capital Global Blood Therapeutics initiated with an Outperform at RBC Capital 11/18/20 Cantor Fitzgerald Global Blood Therapeutics price target lowered to $120 from $133 at Cantor Fitzgerald GBT Global Blood Therapeutics $50.81 / +0.83 (+1.66%) 11/05/20 Global Blood Therapeutics reports Q3 EPS ,(97c) consensus (73c) 08/05/20 Global Blood Therapeutics reports Q2 EPS (86c), consensus ($1.15) GBT Global Blood Therapeutics $50.81 / +0.83 (+1.66%) 11/06/20 Fly Intel: Wall Street's top stories for Friday 11/06/20 Fly Intel: Wall Street's top stories at midday 11/06/20 Square, AMD upgrades among today's top calls on Wall Street
Recommendations	Omnicell price target raised to $140 from $125 at Benchmark » 04:57 01/20/21 01/20 04:57 01/20/21 04:57 OMCL Omnicell $121.56 / +0.71 (+0.59%) Benchmark analyst Bill… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Periodicals On The Fly Events OMCL Omnicell $121.56 / +0.71 (+0.59%) 12/08/20 Omnicell jumps 16.5% to $128 after reported takeover interest from Baxter 08/12/20 Omnicell to acquire 340B Link business from PSG for $225M 07/28/20 Omnicell remains unable to provide FY20 guidance at this time 07/28/20 Omnicell confident in overall health of business OMCL Omnicell $121.56 / +0.71 (+0.59%) 01/14/21 Craig-Hallum Omnicell price target raised to $142 from $100 at Craig-Hallum 12/09/20 Piper Sandler Pontential Baxter, Omnicell deal makes sense, says Piper Sandler 12/09/20 Benchmark Omnicell price target raised to $125 from $100 at Benchmark 12/08/20 Berenberg Berenberg starts four healthcare technology companies with Buy ratings OMCL Omnicell $121.56 / +0.71 (+0.59%) 01/13/21 Omnicell sees FY21EPS $3.38-$3.58, consensus $3.10 01/13/21 Omnicell raises FY20 EPS view to $2.46-$2.51, consensus $2.38 01/13/21 Omnicell raises FY20 EPS view to $2.46-$2.51, consensus $2.38 10/27/20 Omnicell sees FY21 revenue $1.015B-$1.045B, consensus $990.76M OMCL Omnicell $121.56 / +0.71 (+0.59%) 12/09/20 Baxter willing to pay over $125 per share for Omnicell, CNBC reports 12/09/20 Baxter not willing to go hostile to acquire Omnicell, CNBC reports 12/09/20 Omnicell board rejected Baxter takeover bid, CNBC reports 12/09/20 Baxter willing to pay over $125 per share for Omnicell, CNBC reports OMCL Omnicell $121.56 / +0.71 (+0.59%) 12/09/20 Fly Intel: Wall Street's top stories for Wednesday 12/09/20 Fly Intel: Wall Street's top stories at midday 12/09/20 Fly Intel: Pre-market Movers 12/08/20 Fly Intel: After-Hours Movers 02/01/21 Omnicell - OMCL
Upgrade	Lumentum upgraded to Buy from Neutral at Goldman Sachs » 04:55 01/20/21 01/20 04:55 01/20/21 04:55 LITE Lumentum $94.50 / -11.69 (-11.01%) , COHR Coherent $197.01 / +45.09 (+29.68%) Goldman Sachs analyst Rod… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Periodicals On The Fly Events Options LITE COHR LITE Lumentum $94.50 / -11.69 (-11.01%) 01/19/21 Lumentum to acquire Coherent in $5.7B cash and stock transaction, sees accretion 11/16/20 Lumentum acquires TriLumina assets; terms not disclosed 09/04/20 FCC says U.S. rural telecom networks need $1.84B to remove Huawei, ZTE equipment 08/11/20 Lumentum CEO says 'better than projected results' in Q4 COHR Coherent $197.01 / +45.09 (+29.68%) 01/19/21 Lumentum to acquire Coherent in $5.7B cash and stock transaction, sees accretion 12/16/20 Coherent, II-VI enter supply agreement 12/16/20 II-VI, Coherent enter supply agreement for automotive laser welding solutions 11/10/20 Coherent CEO says 'cautiously optimistic on 5G upgrade cycle LITE COHR LITE Lumentum $94.50 / -11.69 (-11.01%) 01/19/21 Craig-Hallum Lumentum acquisition of Coherent 'a good fit in many ways,' says Craig-Hallum 01/12/21 MKM Partners Lumentum price target raised to $138 from $120 at MKM Partners 01/12/21 Susquehanna Susquehanna names top five M&A candidates in Semi space 01/11/21 B. Riley Securities Lumentum price target raised to $123 from $101 at B. Riley Securities COHR Coherent $197.01 / +45.09 (+29.68%) 01/19/21 Craig-Hallum Lumentum acquisition of Coherent 'a good fit in many ways,' says Craig-Hallum 01/12/21 Barclays Coherent downgraded to Underweight from Equal Weight at Barclays 11/12/20 Longbow Coherent downgraded to Neutral ahead of transition year at Longbow 11/12/20 Longbow Coherent downgraded to Neutral from Buy at Longbow LITE COHR LITE Lumentum $94.50 / -11.69 (-11.01%) 01/19/21 Lumentum reports preliminary Q2 EPS $1.91-$1.99, consensus $1.82 11/02/20 Lumentum sees Q2 non-GAAP EPS $1.70-$1.90, consensus $1.60 11/02/20 Lumentum reports Q1 non-GAAP EPS $1.78, consensus $1.47 08/11/20 Lumentum sees Q1 adjusted EPS $1.40-$1.55, consensus $1.33 COHR Coherent $197.01 / +45.09 (+29.68%) 01/19/21 Coherent reports preliminary Q1 revenue $325M-$327M, consensus $313.09M 11/10/20 Coherent sees Q1 revenue $300M-$320M, consensus $341.28M 11/10/20 Coherent reports Q4 adjusted EPS $1.01, consensus 80c 08/04/20 Coherent sees Q4 revenue $290M-$320M, consensus $325.49M LITE COHR LITE Lumentum $94.50 / -11.69 (-11.01%) 01/19/21 NeoPhotonics speculated as potential takeover target at Dealreporter 01/18/21 Lumentum in advanced talks to acquire Coherent, WSJ reports 12/03/20 U.S. in talks with Huawei CFO to settle charges, WSJ reports 11/23/20 U.K. considers Huawei installation ban in 2021, Bloomberg says COHR Coherent $197.01 / +45.09 (+29.68%) 01/19/21 NeoPhotonics speculated as potential takeover target at Dealreporter 01/18/21 Lumentum in advanced talks to acquire Coherent, WSJ reports LITE COHR LITE Lumentum $94.50 / -11.69 (-11.01%) 01/19/21 Fly Intel: Wall Street's top stories for Tuesday 01/19/21 Lumentum slides after announcing $5.7B merger deal with Coherent 01/19/21 Fly Intel: Wall Street's top stories at midday 01/19/21 Fly Intel: Pre-market Movers COHR Coherent $197.01 / +45.09 (+29.68%) 01/19/21 Fly Intel: Wall Street's top stories for Tuesday 01/19/21 Lumentum slides after announcing $5.7B merger deal with Coherent 01/19/21 Fly Intel: Wall Street's top stories at midday 01/19/21 Fly Intel: Pre-market Movers 02/11/21 Technology & Internet Virtual Conference 02/02/21 Lumentum - LITE LITE LITE Lumentum $94.50 / -11.69 (-11.01%) 01/05/21 Lumentum call volume above normal and directionally bullish 08/17/20 Lumentum put volume heavy and directionally bearish 08/03/20 Lumentum call volume above normal and directionally bullish

Events

Earnings calls, analyst events, roadshows and more

Today at 07:00

MBA Mortgage Applications: Purchase Index W/W: 1/15/2021 Government Event
Today at 07:00

MBA Mortgage Applications: Refinance Index W/W: 1/15/2021 Government Event
Today at 07:00

MBA Mortgage Applications: Composite Index W/W: 1/15/2021 Government Event
CALT
Today at 07:00

Calliditas Therapeutics Firm Sponsored Meetings

Virtual Meeting
CFG
Today at 08:00

Citizens Financial - CFG Conference Calls
BK
Today at 08:00

BNY Mellon - BK Conference Calls
MESO
Today at 08:00

Mesoblast - MESO Conference Calls
Today at 08:00

Homebuilders Industry Meetings

Virtual Meeting
FNB
Today at 08:15

F.N.B. - FNB Conference Calls
MS
Today at 08:30

Morgan Stanley - MS Conference Calls

View All Events »

1 of

Syndicate

This week’s upcoming IPOs and secondary offerings

Priced
Not Priced

Mon	No deals
Tues	DSS X DSS Document Security Spot Secondary Managers: Aegis Priced at: $3.60 6.67M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial
Wed	No deals
Thurs	No deals
Fri	No deals

Mon	No deals
Tues	BDGE X BDGE Bridge Bancorp Block Trade Managers: Morgan Stanley $25.50-26.50 700K Shares TCRR X TCRR TCR2 Therapeutics Secondary Managers: Goldman Sachs, Jefferies, Piper Sandler & BMO Capital $32.80 Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial ACRS X ACRS Aclaris Therapeutics Spot Secondary Managers: Cantor Fitzgerald & William Blair, H.C. Wainwright $17.00-18.00 Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial ACRX X ACRX AcelRx Spot Secondary Managers: Cantor Fitzgerald $1.90-2.00 BLRX X BLRX BioLineRx Spot Secondary Managers: H.C. Wainwright $3.17 4.167M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial BNGO X BNGO Bionano Genomics Spot Secondary Managers: Oppenheimer, BTIG, Ladenburg, Maxim $9.14 CYRX X CYRX Cryoport Spot Secondary Managers: Morgan Stanley, Jefferies, SVB Leerink & UBS $64.18 Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial FULC X FULC Fulcrum Therapeutics Spot Secondary Managers: SVB Leerink, Piper Sandler & Credit Suisse $11.73 Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial LAC X LAC Lithium Americas Spot Secondary Managers: Canaccord, Deutsche Bank, Evercore ISI, Stifel $22.00-23.00 Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial PERI X PERI Perion Network Spot Secondary Managers: Oppenheimer, Stifel, Roth Capital, LAKE $13.96 Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial SYRS X SYRS Syros Pharmaceuticals Spot Secondary Managers: Cowen & Piper Sandler $14.95 Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial
Wed	DFH X DFH Dream Finders Homes IPO Managers: BofA, RBC Capital & BTIG, Builder Advisor, Zelman, TCB Capital, Wedbush $12.00-15.00 9.6M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial MYTE X MYTE Mytheresa IPO Managers: Morgan Stanley & JPMorgan, Credit Suisse, UBS, Jefferies, Cowen $24.00-26.00 15.647M Shares Special Comments Ratings Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial RLX X RLX RLX Technology IPO Managers: Citi, China Renaissance $8.00-10.00 116.5M Shares ATHA X ATHA Athira Pharma Secondary Managers: Goldman Sachs, Jefferies, Stifel & JMP Securities $26.55 4M Shares CDNA X CDNA CareDx Secondary Managers: Goldman Sachs & Jefferies, Raymond James, BTIG, Craig-Hallum, H.C. Wainwright $93.33 Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial CMRX X CMRX Chimerix Secondary Managers: Jefferies & Cowen, H.C. Wainwright, JonesTrading $8.10 Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial CTMX X CTMX CytomX Therapeutics Secondary Managers: JPMorgan, Cowen & Piper Sandler $8.48 Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial CYRX X CYRX Cryoport Secondary Managers: Morgan Stanley, Jefferies, SVB Leerink & UBS $76.12 Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial DYN X DYN Dyne Therapeutics Secondary Managers: JPMorgan, Jefferies, Piper Sandler & Stifel $28.61 5.5M Shares EDIT X EDIT Editas Medicine Secondary Managers: JPMorgan & Morgan Stanley, Cowen, Credit Suisse $72.11 3.5M Shares MRUS X MRUS Merus Secondary Managers: Jefferies & SVB Leerink $24.71 Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial
Thurs	PAX X PAX Patria IPO Managers: JPMorgan, BofA & Credit Suisse, Goldman Sachs, Bradesco BBI, BTG Pactual, ITAU, Keefe Bruyette, Santander, XP $14.00-16.00 26.65M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial AZEK X AZEK Azek Secondary Managers: Barclays, BofA, Goldman Sachs & Jefferies $42.25 17.5M Shares CRSR X CRSR Corsair Gaming Secondary Managers: Goldman Sachs, Barclays, Credit Suisse, Macquarie, Baird, Cowen, & Stifel, Wedbush, Academy Securities $37.73 7.5M Shares PASG X PASG Passage Bio Secondary Managers: JPMorgan, Goldman Sachs & Cowen, Wedbush, Chardan $29.05 7M Shares
Fri	No deals

View All Syndicate Announcements »

Piedmont Office Realty reports Q4 core FFO 46c, consensus 45c

TODAY'S FREE FLY STORIES

Get Full Fly Access